| 000 | 01138 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250515182314.0 | ||
| 264 | 0 | _c20101108 | |
| 008 | 201011s 0 0 eng d | ||
| 022 | _a1099-1050 | ||
| 024 | 7 |
_a10.1002/hec.1538 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVernon, John A | |
| 245 | 0 | 0 |
_aDrug development costs when financial risk is measured using the Fama-French three-factor model. _h[electronic resource] |
| 260 |
_bHealth economics _cAug 2010 |
||
| 300 |
_a1002-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aCapital Financing _xeconomics |
| 650 | 0 | 4 |
_aCosts and Cost Analysis _xmethods |
| 650 | 0 | 4 |
_aDrug Approval _xeconomics |
| 650 | 0 | 4 |
_aDrug Discovery _xeconomics |
| 650 | 0 | 4 |
_aDrug Evaluation _xeconomics |
| 650 | 0 | 4 |
_aDrug Industry _xeconomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Econometric |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aGolec, Joseph H | |
| 700 | 1 | _aDimasi, Joseph A | |
| 773 | 0 |
_tHealth economics _gvol. 19 _gno. 8 _gp. 1002-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hec.1538 _zAvailable from publisher's website |
| 999 |
_c19062268 _d19062268 |
||